Voyager's gene therapy aims to turn back the clock so advanced Parkinson's patients respond better and longer to the standard drug used to treat the brain disease.
Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
I spent the weekend with thousands of blood disease researchers. This is what happened.
Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.